This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Croston, G. E. Articles by Briggs, M. R. Search for Related Content PubMed PubMed Citation Articles by Croston, G. E. Articles by Briggs, M. R. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB ESTRADIOL Genetics Home Reference

Androgen Receptor-Mediated Antagonism of Estrogen-Dependent Low Density Lipoprotein Receptor Transcription in Cultured Hepatocytes

Ligand Pharmaceuticals, San Diego, California 92121

Address all correspondence and requests for reprints to: Dr. Michael Briggs, Ligand Pharmaceuticals, 9393 Towne Centre Drive, San Diego, California 92121. E-mail: mbriggs{at}ligand.com

Postmenopausal women receiving hormone replacement therapy have a lower risk of coronary heart disease than women who do not receive hormone treatment. Multiple mechanisms are likely to underlie estrogen’s cardioprotective action, including lowering of plasma low density lipoprotein (LDL) cholesterol. Using an in vitro system exhibiting normal regulation of LDL receptor (LDLR) gene transcription, we show that 17ß-estradiol activates the LDLR promoter in transiently transfected HepG2 cells. LDLR activation by estrogen in HepG2 cells is dependent on the presence of exogenous estrogen receptor, and the estrogen-responsive region of the LDLR promoter colocalizes with the sterol response element previously identified. The estrogen response is concentration dependent, saturable, and sensitive to antagonism by estrogen receptor antagonists. Further, we show that compounds with androgen receptor agonist activity attenuate the estrogen-induced up-regulation of LDLR in our model system. Progestins with androgen receptor agonist activity, such as medroxyprogesterone acetate, also suppress estrogen’s effects on LDLR expression through their androgenic properties. Characterization of the interplay between these hormone receptors on the LDLR in vitro system may allow a better understanding of the actions of sex steroids on LDLR gene expression and their roles in cardiovascular disease.

This article has been cited by other articles:

				L. Bjornstrom and M. Sjoberg Mechanisms of Estrogen Receptor Signaling: Convergence of Genomic and Nongenomic Actions on Target Genes Mol. Endocrinol., April 1, 2005; 19(4): 833 - 842. [Abstract] [Full Text] [PDF]

				H. R. Kast-Woelbern, S. L. Dana, R. M. Cesario, L. Sun, L. Y. de Grandpre, M. E. Brooks, D. L. Osburn, A. Reifel-Miller, K. Klausing, and M. D. Leibowitz Rosiglitazone Induction of Insig-1 in White Adipose Tissue Reveals a Novel Interplay of Peroxisome Proliferator-activated Receptor {gamma} and Sterol Regulatory Element-binding Protein in the Regulation of Adipogenesis J. Biol. Chem., June 4, 2004; 279(23): 23908 - 23915. [Abstract] [Full Text] [PDF]

				M. Leblanc, M.-C. Belanger, P. Julien, A. Tchernof, C. Labrie, A. Belanger, and F. Labrie Plasma Lipoprotein Profile in the Male Cynomolgus Monkey under Normal, Hypogonadal, and Combined Androgen Blockade Conditions J. Clin. Endocrinol. Metab., April 1, 2004; 89(4): 1849 - 1857. [Abstract] [Full Text] [PDF]

				G. Min, H. Kim, Y. Bae, L. Petz, and J. K. Kemper Inhibitory Cross-talk between Estrogen Receptor (ER) and Constitutively Activated Androstane Receptor (CAR). CAR INHIBITS ER-MEDIATED SIGNALING PATHWAY BY SQUELCHING p160 COACTIVATORS J. Biol. Chem., September 6, 2002; 277(37): 34626 - 34633. [Abstract] [Full Text] [PDF]

				H. Jansen, A. J. M. Verhoeven, and E. J. G. Sijbrands Hepatic lipase: a pro- or anti-atherogenic protein? J. Lipid Res., September 1, 2002; 43(9): 1352 - 1362. [Abstract] [Full Text] [PDF]

				L. J. Wilcox, N. M. Borradaile, L. E. de Dreu, and M. W. Huff Secretion of hepatocyte apoB is inhibited by the flavonoids, naringenin and hesperetin, via reduced activity and expression of ACAT2 and MTP J. Lipid Res., May 1, 2001; 42(5): 725 - 734. [Abstract] [Full Text]

				C. E. Hudson, B. A. Schulte, T. R. Sutter, and J. S. Norris Steroid hormones modulate expression of cytochrome P450 enzymes in male hamster reproductive tract and leiomyosarcomas Carcinogenesis, May 1, 2001; 22(5): 763 - 770. [Abstract] [Full Text] [PDF]

				C. Li, M. R. Briggs, T. E. Ahlborn, F. B. Kraemer, and J. Liu Requirement of Sp1 and Estrogen Receptor {{alpha}} Interaction in 17{beta}-Estradiol-Mediated Transcriptional Activation of the Low Density Lipoprotein Receptor Gene Expression Endocrinology, April 1, 2001; 142(4): 1546 - 1553. [Abstract] [Full Text]

				A. Karjalainen, J. Heikkinen, M. J. Savolainen, A.-C. Backstrom, and Y. A. Kesaniemi Mechanisms Regulating LDL Metabolism in Subjects on Peroral and Transdermal Estrogen Replacement Therapy Arterioscler Thromb Vasc Biol, April 1, 2000; 20(4): 1101 - 1106. [Abstract] [Full Text] [PDF]

				W. Seol, B. Hanstein, M. Brown, and D. D. Moore Inhibition of Estrogen Receptor Action by the Orphan Receptor SHP (Short Heterodimer Partner) Mol. Endocrinol., October 1, 1998; 12(10): 1551 - 1557. [Abstract] [Full Text]